Characteristic | n = 12 |
---|---|
Age (years) | 65 ± 11 |
Male (%) | 6 (50) |
BMI (kg/m2) | 28.2 ± 5.4 |
SBP (mmHg) | 141 ± 7.6 |
DBP (mmHg) | 74.9 ± 11.0 |
HbA1c (%) | 6.9 ± 0.70 |
FPG (mg/dL) | 139.5 ± 40.5 |
TC (mg/dL) | 176.4 ± 26.8 |
LDL-C (mg/dL) | 97.3 ± 25.8 |
HDL-C (mg/dL) | 45.5 ± 9.1 |
TG (mg/dL) | 184.7 ± 34.8 |
EPA/AA | 0.30 ± 0.19 |
DHA/AA | 0.75 ± 0.16 |
AST (IU/L) | 24.5 ± 13.0 |
ALT (IU/L) | 32.5 ± 31.7 |
Cre (mg/dL) | 0.81 ± 0.30 |
Antidiabetic medications (%) | Â |
 DPP-4 inhibitor | 12 (100) |
 Metformin | 6 (50) |
 Glimepiride | 3 (25) |
 Repaglinide | 1 (8.3) |
 Miglitol | 3 (25) |
 Ipragliflozin | 1 (8.3) |
 Insulin Aspart | 2 (16.6) |
 Insulin Detemir | 1 (8.3) |
 Insulin Glargine | 1 (8.3) |
Hypolipidemic agents | Â |
 Rosuvastatin | 6 (50) |
 Atorvastatin | 2 (16.6) |
 Pravastatin | 2 (16.6) |
 Pitavastatin | 2 (16.6) |
Antihypertensive agents | 9 (75) |
Microvascular complications | Â |
 Diabetes nephropathy | 3 (25) |
Macrovascular complications | Â |
 Cerebral infarction | 1 (8.3) |